Vanda Pharmaceuticals Stock Price, News & Analysis (NASDAQ:VNDA)

$13.05 0.10 (0.77 %)
(As of 11/21/2017 02:54 AM ET)
Previous Close$12.95
Today's Range$12.85 - $13.13
52-Week Range$11.90 - $18.99
Volume352,100 shs
Average Volume556,658 shs
Market Capitalization$586.30 million
P/E RatioN/A
Dividend YieldN/A
Beta1.36

About Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals logoVanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Sector: Healthcare
  • Symbol: NASDAQ:VNDA
  • CUSIP: 92165910
  • Web: www.vandapharmaceuticals.com
Debt:
  • Current Ratio: 2.37%
  • Quick Ratio: 2.36%
Sales & Book Value:
  • Annual Sales: $146.02 million
  • Price / Sales: 4.02
  • Book Value: $2.99 per share
  • Price / Book: 4.36
Profitability:
  • Trailing EPS: ($0.32)
  • Net Income: $-18,010,000.00
  • Net Margins: -9.01%
  • Return on Equity: -10.99%
  • Return on Assets: -6.89%
Misc:
  • Employees: 142
  • Outstanding Shares: 44,930,000
 

Frequently Asked Questions for Vanda Pharmaceuticals (NASDAQ:VNDA)

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.10). The biopharmaceutical company earned $41.30 million during the quarter, compared to the consensus estimate of $43.90 million. Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The firm's revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period last year, the business posted ($0.01) EPS. View Vanda Pharmaceuticals' Earnings History.

When will Vanda Pharmaceuticals make its next earnings announcement?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 13th 2018. View Earnings Estimates for Vanda Pharmaceuticals.

Where is Vanda Pharmaceuticals' stock going? Where will Vanda Pharmaceuticals' stock price be in 2017?

5 equities research analysts have issued 12-month price objectives for Vanda Pharmaceuticals' shares. Their predictions range from $18.00 to $26.00. On average, they anticipate Vanda Pharmaceuticals' share price to reach $22.20 in the next year. View Analyst Ratings for Vanda Pharmaceuticals.

Who are some of Vanda Pharmaceuticals' key competitors?

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:

  • H. Thomas Watkins, Independent Chairman of the Board (Age 64)
  • Mihael Hristos Polymeropoulos M.D., President, Chief Executive Officer, Director (Age 57)
  • James Patrick Kelly, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)
  • Gian Piero Reverberi, Senior Vice President, Chief Compliance Officer (Age 51)
  • Richard L. Gulino, Senior Vice President, General Counsel, Secretary (Age 54)
  • Gunther Birznieks, Senior Vice President - Business Development (Age 48)
  • Kenneth M. Bate, Independent Director (Age 66)
  • Michael F. Cola, Independent Director (Age 57)
  • Richard W. Dugan, Independent Director (Age 75)
  • Vincent J. Milano, Independent Director (Age 53)

Who owns Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Macquarie Group Ltd. (4.21%), Rothschild Asset Management Inc. (2.93%), Prudential Financial Inc. (1.31%), Schwab Charles Investment Management Inc. (1.05%), Stonepine Capital Management LLC (0.67%) and Sei Investments Co. (0.60%). Company insiders that own Vanda Pharmaceuticals stock include James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos, Paolo Baroldi and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.

Who sold Vanda Pharmaceuticals stock? Who is selling Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Stonepine Capital Management LLC, JPMorgan Chase & Co., Russell Investments Group Ltd., Cheyne Capital Management UK LLP, OxFORD Asset Management LLP, Columbus Circle Investors and California State Teachers Retirement System. View Insider Buying and Selling for Vanda Pharmaceuticals.

Who bought Vanda Pharmaceuticals stock? Who is buying Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Rothschild Asset Management Inc., Sei Investments Co., Macquarie Group Ltd., Cortina Asset Management LLC, University of Notre Dame DU Lac, Foundry Partners LLC, 361 Capital LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Vanda Pharmaceuticals.

How do I buy Vanda Pharmaceuticals stock?

Shares of Vanda Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of Vanda Pharmaceuticals stock can currently be purchased for approximately $13.05.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $586.30 million and generates $146.02 million in revenue each year. The biopharmaceutical company earns $-18,010,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Vanda Pharmaceuticals employs 142 workers across the globe.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 Pennsylvania Ave NW Ste 300E, WASHINGTON, DC 20037-1754, United States. The biopharmaceutical company can be reached via phone at +1-202-7343400 or via email at [email protected]


MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  388
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.20 (70.11% upside)

Consensus Price Target History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Price Target History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Analysts' Ratings History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/12/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$25.00N/AView Rating Details
10/19/2017Piper Jaffray CompaniesSet Price TargetBuy$26.00N/AView Rating Details
8/29/2017Jefferies Group LLCReiterated RatingBuy$21.00HighView Rating Details
8/3/2017HC WainwrightSet Price TargetBuy$18.00HighView Rating Details
4/12/2017CIBCReiterated RatingOutperform -> Outperform$21.00LowView Rating Details
11/9/2016AegisInitiated CoverageBuy$24.00N/AView Rating Details
10/10/2016Brean CapitalSet Price TargetBuy$24.00N/AView Rating Details
8/26/2016JMP SecuritiesBoost Price TargetMarket Outperform$18.00 -> $22.00N/AView Rating Details
3/14/2016Canaccord GenuityReiterated RatingBuy$18.00N/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Vanda Pharmaceuticals (NASDAQ:VNDA)

Earnings by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Earnings History by Quarter for Vanda Pharmaceuticals (NASDAQ VNDA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2018($0.11)N/AView Earnings Details
11/7/2017Q3 2017($0.10)($0.10)$43.90 million$41.30 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.21)($0.03)$40.31 million$42.06 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.13)($0.17)$38.35 million$37.42 millionViewListenView Earnings Details
2/15/2017Q416($0.06)($0.01)$39.38 million$38.24 millionViewListenView Earnings Details
11/2/2016Q316($0.14)($0.01)$38.05 million$38.48 millionViewListenView Earnings Details
7/27/2016Q216($0.23)($0.11)$36.03 million$36.02 millionViewListenView Earnings Details
5/4/2016Q116($0.24)($0.17)$32.48 million$33.30 millionViewListenView Earnings Details
2/10/2016Q415($0.26)($0.23)$31.34 million$31.85 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.11)$28.58 million$28.34 millionViewListenView Earnings Details
7/29/2015Q2($0.32)($0.01)$24.55 million$27.60 millionViewListenView Earnings Details
5/6/2015Q1($0.25)($0.24)$20.18 million$22.20 millionViewListenView Earnings Details
2/19/2015Q4$0.56($0.36)$35.57 million$15.40 millionViewListenView Earnings Details
10/27/2014Q314($0.39)($0.04)$12.20 million$14.80 millionViewListenView Earnings Details
8/7/2014Q2($0.70)($0.64)$10.00 million$10.80 millionViewListenView Earnings Details
5/8/2014Q1($0.29)($0.79)$8.50 million$9.10 millionViewListenView Earnings Details
2/13/2014Q413($0.20)($0.23)$8.50 million$8.80 millionViewListenView Earnings Details
11/7/2013Q313($0.30)($0.43)$8.45 million$8.70 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.22)($0.26)$8.43 million$8.30 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.25)($0.15)$8.42 million$8.10 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.22)($0.23)$8.60 million$7.90 millionViewListenView Earnings Details
11/7/2012Q312($0.22)($0.19)$8.40 million$8.28 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.28)ViewN/AView Earnings Details
5/8/2012($0.16)($0.28)ViewN/AView Earnings Details
2/14/2012($0.19)($0.20)ViewN/AView Earnings Details
11/4/2011($0.12)($0.11)ViewN/AView Earnings Details
8/4/2011($0.07)($0.05)ViewN/AView Earnings Details
2/10/2011($0.02)$0.08ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)
2017 EPS Consensus Estimate: ($0.62)
2018 EPS Consensus Estimate: ($0.20)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.18)($0.15)($0.17)
Q2 20172($0.27)($0.20)($0.24)
Q3 20172($0.13)($0.08)($0.11)
Q4 20172($0.13)($0.10)($0.12)
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.07)($0.07)($0.07)
Q3 20181$0.00$0.00$0.00
Q4 20181$0.04$0.04$0.04
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vanda Pharmaceuticals (NASDAQ:VNDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Vanda Pharmaceuticals (NASDAQ VNDA)

Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 92.84%
Insider Trades by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Insider Trades by Quarter for Vanda Pharmaceuticals (NASDAQ VNDA)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Richard L GulinoSVPSell10,900$15.51$169,059.00View SEC Filing  
9/23/2016James E FlynnInsiderSell1,120,461$16.56$18,554,834.16View SEC Filing  
9/19/2016James E FlynnInsiderSell547,886$15.66$8,579,894.76View SEC Filing  
1/4/2016James Patrick KellyCFOSell9,564$8.96$85,693.44View SEC Filing  
1/4/2016Mihael Hristos PolymeropoulosCEOSell21,353$8.96$191,322.88View SEC Filing  
1/4/2016Paolo BaroldiSVPSell12,380$8.96$110,924.80View SEC Filing  
12/11/2015James E FlynnInsiderBuy1,201,364$8.38$10,067,430.32View SEC Filing  
9/10/2015Mihael Hristos PolymeropoulosCEOSell131,739$12.68$1,670,450.52View SEC Filing  
5/22/2015Mihael Hristos PolymeropoulosCEOSell186,395$10.36$1,931,052.20View SEC Filing  
3/9/2015Richard W DuganDirectorSell4,804$10.69$51,354.76View SEC Filing  
12/23/2014James E FlynnInsiderBuy162,014$14.40$2,333,001.60View SEC Filing  
3/14/2014Thomas WatkinsDirectorSell35,000$17.66$618,100.00View SEC Filing  
11/21/2013Robert RepellaSVPSell107,500$12.03$1,293,225.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Vanda Pharmaceuticals (NASDAQ VNDA)

Source:
DateHeadline
Zacks: Brokerages Expect Vanda Pharmaceuticals Inc. (VNDA) Will Announce Quarterly Sales of $44.00 MillionZacks: Brokerages Expect Vanda Pharmaceuticals Inc. (VNDA) Will Announce Quarterly Sales of $44.00 Million
www.americanbankingnews.com - November 19 at 8:42 AM
Vanda Pharmaceuticals Inc. (VNDA) Expected to Post Earnings of -$0.12 Per ShareVanda Pharmaceuticals Inc. (VNDA) Expected to Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - November 17 at 3:28 PM
Vanda Pharmaceuticals Inc. (VNDA) to Post Q3 2018 Earnings of $0.00 Per Share, Oppenheimer Holdings ForecastsVanda Pharmaceuticals Inc. (VNDA) to Post Q3 2018 Earnings of $0.00 Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - November 14 at 10:48 AM
Oppenheimer Holdings, Inc. Reaffirms "Buy" Rating for Vanda Pharmaceuticals Inc. (VNDA)Oppenheimer Holdings, Inc. Reaffirms "Buy" Rating for Vanda Pharmaceuticals Inc. (VNDA)
www.americanbankingnews.com - November 13 at 2:27 PM
FDA Nod For BMYs Sprycel, ARNA To Report Data In Q1, MYL Delists From TASEFDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE
www.rttnews.com - November 13 at 11:12 AM
Vanda Pharmaceuticals Announces Participation at November 2017 Investor ConferencesVanda Pharmaceuticals Announces Participation at November 2017 Investor Conferences
finance.yahoo.com - November 13 at 11:12 AM
Reviewing Vanda Pharmaceuticals (VNDA) & Its PeersReviewing Vanda Pharmaceuticals (VNDA) & Its Peers
www.americanbankingnews.com - November 13 at 3:34 AM
FY2017 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Boosted by AnalystFY2017 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Boosted by Analyst
www.americanbankingnews.com - November 13 at 1:48 AM
Jefferies Group Comments on Vanda Pharmaceuticals Inc.s FY2020 Earnings (VNDA)Jefferies Group Comments on Vanda Pharmaceuticals Inc.'s FY2020 Earnings (VNDA)
www.americanbankingnews.com - November 10 at 7:46 PM
Traders Purchase Large Volume of Put Options on Vanda Pharmaceuticals (VNDA)Traders Purchase Large Volume of Put Options on Vanda Pharmaceuticals (VNDA)
www.americanbankingnews.com - November 10 at 1:08 AM
Edited Transcript of VNDA earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of VNDA earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 9:35 AM
Vanda Pharmaceuticals (VNDA) CEO Mihael Polymeropoulos on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaVanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 4:19 AM
Vanda Pharmaceuticals Inc. (VNDA) Announces Quarterly  Earnings ResultsVanda Pharmaceuticals Inc. (VNDA) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 7 at 6:54 PM
Vanda Pharmaceuticals Reports Third Quarter 2017 Financial ResultsVanda Pharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 6:12 PM
Vanda reports 3Q lossVanda reports 3Q loss
finance.yahoo.com - November 7 at 6:12 PM
Vanda Pharmaceuticals Inc. to Host Earnings CallVanda Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 1:09 PM
Q1 2018 EPS Estimates for Vanda Pharmaceuticals Inc. Lowered by Analyst (VNDA)Q1 2018 EPS Estimates for Vanda Pharmaceuticals Inc. Lowered by Analyst (VNDA)
www.americanbankingnews.com - November 1 at 2:02 PM
Oppenheimer Holdings Analysts Lower Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)Oppenheimer Holdings Analysts Lower Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)
www.americanbankingnews.com - October 31 at 2:02 PM
$44.40 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter$44.40 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - October 30 at 4:48 AM
Vanda Pharmaceuticals Inc. (VNDA) Given Average Recommendation of "Buy" by BrokeragesVanda Pharmaceuticals Inc. (VNDA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 29 at 11:42 AM
ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 27, 2017ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 27, 2017
finance.yahoo.com - October 28 at 8:03 AM
Vanda Pharmaceuticals Inc. (VNDA) Stock Rating Lowered by Zacks Investment ResearchVanda Pharmaceuticals Inc. (VNDA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - October 26 at 9:00 AM
Vanda Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017Vanda Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017
finance.yahoo.com - October 24 at 9:21 PM
Vanda Pharmaceuticals Inc. (VNDA) Set to Announce Earnings on TuesdayVanda Pharmaceuticals Inc. (VNDA) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 24 at 5:48 AM
Vanda Pharmaceuticals Inc. (VNDA) Downgraded by Zacks Investment ResearchVanda Pharmaceuticals Inc. (VNDA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 22 at 7:14 PM
Piper Jaffray Companies Analysts Give Vanda Pharmaceuticals Inc. (VNDA) a $26.00 Price TargetPiper Jaffray Companies Analysts Give Vanda Pharmaceuticals Inc. (VNDA) a $26.00 Price Target
www.americanbankingnews.com - October 21 at 3:34 PM
Vanda Pharmaceuticals (VNDA) versus Its Rivals Financial SurveyVanda Pharmaceuticals (VNDA) versus Its Rivals Financial Survey
www.americanbankingnews.com - October 19 at 9:06 AM
Vanda Pharmaceuticals Inc. (VNDA) Upgraded to "Buy" at Zacks Investment ResearchVanda Pharmaceuticals Inc. (VNDA) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - October 18 at 10:58 AM
ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 17, 2017ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 17, 2017
finance.yahoo.com - October 18 at 10:22 AM
Oppenheimer Holdings Comments on Vanda Pharmaceuticals Inc.s Q1 2018 Earnings (VNDA)Oppenheimer Holdings Comments on Vanda Pharmaceuticals Inc.'s Q1 2018 Earnings (VNDA)
www.americanbankingnews.com - October 12 at 11:38 AM
Vanda Pharmaceuticals Inc. (VNDA) Downgraded by Zacks Investment Research to SellVanda Pharmaceuticals Inc. (VNDA) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - October 12 at 10:22 AM
Oppenheimer Holdings Weighs in on Vanda Pharmaceuticals Inc.s Q3 2018 Earnings (VNDA)Oppenheimer Holdings Weighs in on Vanda Pharmaceuticals Inc.'s Q3 2018 Earnings (VNDA)
www.americanbankingnews.com - October 11 at 12:08 PM
 Brokerages Anticipate Vanda Pharmaceuticals Inc. (VNDA) Will Announce Quarterly Sales of $44.40 Million Brokerages Anticipate Vanda Pharmaceuticals Inc. (VNDA) Will Announce Quarterly Sales of $44.40 Million
www.americanbankingnews.com - October 11 at 11:52 AM
Vanda Pharmaceuticals Announces Participation at the ... - PR Newswire (press release)Vanda Pharmaceuticals Announces Participation at the ... - PR Newswire (press release)
www.prnewswire.com - October 11 at 9:19 AM
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : October 10, 2017Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : October 10, 2017
finance.yahoo.com - October 11 at 9:19 AM
Vanda Pharmaceuticals Announces Participation at the Oppenheimer Specialty Pharma Summit ConferenceVanda Pharmaceuticals Announces Participation at the Oppenheimer Specialty Pharma Summit Conference
finance.yahoo.com - October 11 at 9:19 AM
Analysts Set Expectations for Vanda Pharmaceuticals Inc.s FY2017 Earnings (VNDA)Analysts Set Expectations for Vanda Pharmaceuticals Inc.'s FY2017 Earnings (VNDA)
www.americanbankingnews.com - October 11 at 8:00 AM
Vanda Pharmaceuticals Inc. (VNDA) Lowered to Hold at Zacks Investment ResearchVanda Pharmaceuticals Inc. (VNDA) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 5 at 9:08 AM
Vanda Pharmaceuticals Inc. (VNDA) Receives Consensus Rating of "Buy" from BrokeragesVanda Pharmaceuticals Inc. (VNDA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 4 at 10:46 AM
Vanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of Itch - PR Newswire (press release)Vanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of Itch - PR Newswire (press release)
www.prnewswire.com - October 4 at 8:45 AM
Vanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of ItchVanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of Itch
finance.yahoo.com - October 3 at 2:37 PM
ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 2, 2017ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 2, 2017
finance.yahoo.com - October 3 at 2:37 PM
Vanda To Present Scientific Posters At World Sleep 2017Vanda To Present Scientific Posters At World Sleep 2017
www.thestreet.com - September 29 at 2:24 PM
$44.50 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter$44.50 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - September 22 at 3:22 AM
These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys?These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys?
finance.yahoo.com - September 19 at 9:22 AM
Vanda Pharmaceuticals (VNDA) Presents At Morgan Stanley 15th Annual Global Healthcare Conference - SlideshowVanda Pharmaceuticals (VNDA) Presents At Morgan Stanley 15th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - September 15 at 11:05 AM
Is It Too Late To Buy Vanda Pharmaceuticals Inc (VNDA)?Is It Too Late To Buy Vanda Pharmaceuticals Inc (VNDA)?
finance.yahoo.com - September 15 at 11:05 AM
Vanda Pharmaceuticals Inc. (VNDA) Earns "Buy" Rating from Oppenheimer Holdings, Inc.Vanda Pharmaceuticals Inc. (VNDA) Earns "Buy" Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 14 at 3:32 PM
Vanda Pharmaceuticals Inc. (VNDA) Price Target Increased to $26.00 by Analysts at Piper Jaffray CompaniesVanda Pharmaceuticals Inc. (VNDA) Price Target Increased to $26.00 by Analysts at Piper Jaffray Companies
www.americanbankingnews.com - September 14 at 9:08 AM
Vanda Pharma shares decline as goal of itch drug study not reached - MarketWatchVanda Pharma shares decline as goal of itch drug study not reached - MarketWatch
www.marketwatch.com - September 13 at 9:00 PM

Social Media

Financials

Chart

Vanda Pharmaceuticals (NASDAQ VNDA) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.